OncoSec Medical Incorporated (ONCS) OncoSec Medical Incorporated (OTC: ONCS) designs and develops novel cancer therapeutic products. The company’s products combine proprietary delivery technology with a novel DNA-based immunotherapeutics, known as OMS ElectroOncology. Its clinical programs include The NeoPulse approach, which is in clinical trials for the treatment of recurrent head, neck and breast cancer; and three clinical trials assessing the cancer-destroying and tissue-sparing properties of the ImmunoPulse technology. For more information, visit the company’s website at www.oncosec.com.